Patents by Inventor Yukari KASE

Yukari KASE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Marine organism-derived extract, compound, and medical composition having niche formation suppressing activity of leukemic stem cells
    Patent number: 10933044
    Abstract: Using the cobblestone area (CA) formation inhibitory activity of human leukemic stem cell-like cells as an indicator, a fraction having the activity has been extracted from the fat-soluble fraction of Porifera, then, a compound having the activity has been isolated and purified from the aforementioned fraction, and then, the structure thereof has been determined, so that a Stelliferin compound comprising a novel compound has been identified. Moreover, it has been found that the isolated and purified Stelliferin compound significantly suppresses the niche formation of leukemic stem cell-like cells derived from human chronic myelogenous leukemia (CML) having resistance to existing antitumor agents and enhances the effects of antitumor agents on the cells.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: March 2, 2021
    Assignees: WASEDA UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yoichi Nakao, Shigetaka Asano, Daisuke Arai, Yukari Kase, Teppei Shimomoto
  • MARINE ORGANISM-DERIVED EXTRACT, COMPOUND, AND MEDICAL COMPOSITION HAVING NICHE FORMATION SUPPRESSING ACTIVITY OF LEUKEMIC STEM CELLS
    Publication number: 20190022045
    Abstract: Using the cobblestone area (CA) formation inhibitory activity of human leukemic stem cell-like cells as an indicator, a fraction having the activity has been extracted from the fat-soluble fraction of Porifera, then, a compound having the activity has been isolated and purified from the aforementioned fraction, and then, the structure thereof has been determined, so that a Stelliferin compound comprising a novel compound has been identified. Moreover, it has been found that the isolated and purified Stelliferin compound significantly suppresses the niche formation of leukemic stem cell-like cells derived from human chronic myelogenous leukemia (CML) having resistance to existing antitumor agents and enhances the effects of antitumor agents on the cells.
    Type: Application
    Filed: January 12, 2017
    Publication date: January 24, 2019
    Applicants: WASEDA UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yoichi NAKAO, Shigetaka ASANO, Daisuke ARAI, Yukari KASE, Teppei SHIMOMOTO